You are here
Open
NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.
If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).
-
CDC/NCHHSTP 056: EHR Algorithm to Identify Persons with HIV Not in Care
Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023Phase I SBIR proposals will be accepted. Fast-track proposals will not be accepted. Phase I clinical trials will not be accepted. Number of anticipated awards: 1 Budget (total costs): Phase I up to $243,500 for up to 6 months; Phase II of up to $1,972,828 and a Phase II duration of up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Page 133 Backgroun ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesCenters for Disease Control and Prevention -
NIH/NCI 460: Evaluation Datasets as Medical Device Development Tools for Testing Cancer Technologies
Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023Fast-Track proposals will NOT be accepted. Direct-to-Phase II proposals will NOT be accepted. Number of anticipated awards: 3-5 Budget (total costs, per award): Page 88 Phase I: up to $400,000 for up to 12 months Phase II: up to $2,000,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary Oncology data science and analytics is a burgeoni ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-DA-24-018: Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional)
Release Date: 05-24-2023Open Date: 10-09-2023Due Date: 11-10-2023Close Date: 11-11-2023In 2020, 40.3 million people aged 12 or older had substance use disorder (SUD) in the past year. Of those, 2.6 million people (6.4%) received any in-person treatment, while 2.2 million (5.4%) received virtual services for substance use treatment. Therefore, an estimated 35 million people did not receive any treatment. To receive treatment, individuals need to receive a diagnosis from a provider, ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-DA-24-017: Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R41/R42 Clinical Trial Optional)
Release Date: 05-24-2023Open Date: 10-09-2023Due Date: 11-09-2023Close Date: 11-10-2023In 2020, 40.3 million people aged 12 or older had substance use disorder (SUD) in the past year. Of those, 2.6 million people (6.4%) received any in-person treatment, while 2.2 million (5.4%) received virtual services for substance use treatment. Therefore, an estimated 35 million people did not receive any treatment. To receive treatment, individuals need to receive a diagnosis from a provider, ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-NS-23-007: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
Release Date: 09-15-2022Open Date: 12-04-2022 Due Dates: Multiple Close Date: 04-05-2025Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
RFA-NS-23-006: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
Release Date: 09-15-2022Open Date: 12-04-2022 Due Dates: Multiple Close Date: 04-05-2025Purpose The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. Specifically, this FOA is focused on applications directed at improving pain measurement ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
CDC/NCIRD 036: Improved Diagnostic Assays for Measles, Mumps, Rubella, and Varicella
Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023Phase I SBIR proposals will be accepted. Fast-track proposals will not be accepted. Phase I clinical trials will not be accepted. Number of anticipated awards: 1 Budget (total costs): Phase I up to $243,500 for up to 6 months; Phase II of up to $1,972,828 and a Phase II duration of up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Background Acute i ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesCenters for Disease Control and Prevention -
PAR-23-268: Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
Release Date: 04-18-2023Open Date: 05-06-2023 Due Dates: Multiple Close Date: 06-07-2025Purpose This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) Phase I and Phase II (Fast track) grant applications. The funding opportunity will utilize a UT1/UT2 cooperative agreement to support SBCs to propose the development of novel extracellular vesicle (EV)-based therapeutic platforms for ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
PAR-23-267: Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
Release Date: 04-18-2023Open Date: 05-06-2023 Due Dates: Multiple Close Date: 06-07-2025Purpose This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) Phase I and Phase II (Fast track and Direct to phase II) grant applications. The funding opportunity will utilize a U43/U44 cooperative agreement to support SBCs to propose the development of novel extracellular vesicle-based therape ...
SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health -
PAR-22-103: Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)
Release Date: 01-21-2022Open Date: 02-28-2022 Due Dates: Multiple Close Date: 12-05-2024Background Currently, there are only three medications (four formulations) approved by the FDA for the treatment of alcohol use disorder (AUD). The need for additional medications to treat those affected by AUD is urgently needed.In addition,alcohol misuseaffects virtually all tissues and is linked with dysfunction and failure of many organs and systems including the liver, heart, pancreas, lung, ...
STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health